Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival: A Prospective, Multicenter, Randomized Trial Comparing Infarct Artery Stenting Plus Abciximab with Stenting Alone

Circulation

Volumn 109, Issue 14, 2004, Pages 1704-1706

  Antoniucci, David ^a   Migliorini, Angela ^a   Parodi, Guido ^a   Valenti, Renato ^a   Rodriguez, Alfredo ^b   Hempel, Albrecht ^c   Memisha, Gentian ^a   Santoro, Giovanni Maria ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Sanatorio Otamendi y Miroli   (Argentina)

^c Bernau Heart Center   (Germany)

Author keywords

Glycoproteins; Myocardial infarction; Stents

Indexed keywords

ABCIXIMAB;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; HEART REINFARCTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; COMORBIDITY; CORONARY STENOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RECURRENCE; RISK FACTORS; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4444384038     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000126284.40075.98     Document Type: Article

References (11)

1. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
2. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1-6.
3. Neumann F-J, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
4. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
5. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
6. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1875-1879.
7. TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
8. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med. 1989;320:618-627.
9. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-741.
10. Eisenberg MJ, Jamal S. Glycoprotein IIb/IIIa inhibition in the setting of acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;42:1-6.
11. Topol EJ, Neumann F-J, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886-1889.